Medical conditions in fibromyalgia patients and their relationship to pregabalin efficacy: pooled analysis of Phase III clinical trials.
Bhadra
Pritha
P
Pfizer Inc., New York, NY 10017, USA. danielle.petersel@pfizer.com
Petersel
Danielle
D
D000328:Adult; D000700:Analgesics / Q000627:therapeutic use*; D017326:Clinical Trials, Phase III as Topic; D015897:Comorbidity; D004305:Dose-Response Relationship, Drug; D005260:Female; D005356:Fibromyalgia / Q000188:drug therapy* / Q000453:epidemiology; D005764:Gastroesophageal Reflux / Q000453:epidemiology; D006261:Headache / Q000453:epidemiology; D006801:Humans; D006967:Hypersensitivity / Q000453:epidemiology; D008297:Male; D001523:Mental Disorders / Q000453:epidemiology; D008875:Middle Aged; D000069583:Pregabalin; D015995:Prevalence; D016032:Randomized Controlled Trials as Topic; D005680:gamma-Aminobutyric Acid / Q000031:analogs & derivatives* / Q000627:therapeutic use
D000700:Analgesics; D000069583:Pregabalin; D005680:gamma-Aminobutyric Acid